Navigation Links
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
Date:2/8/2013

BOULDER, Colo., Feb. 8, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will present at the Leerink Swann Healthcare Conference in New York.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Event:Leerink Swann Healthcare Conference Presenter:Ron Squarer, Chief Executive OfficerDate:Thursday, February 14, 2013Time:8:00 a.m. Eastern Time Location:The Waldorf Astoria, New York, NYWebcast:www.arraybiopharma.comAbout Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. During 2013, Array expects to make substantial progress in generating data to inform registration study decisions for our wholly-owned hematology programs, ARRY-520 and ARRY-614.  Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma which is scheduled to start in April 2013, as well as BRAF mutant melanoma later in 2013 (with Novartis). Also, AstraZeneca recently announced a potential start of a Phase 3 trial with Array-invented selumetinib in non-small cell lung cancer during the second half of 2013.
For more information on Array, please go to www.arraybiopharma.com.

CONTACT: 

Tricia HaugetoArray BioPharma Inc.303-386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
2. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
3. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
6. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
7. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
8. Matinas BioPharma to Present at the NYC Medical Technology Forum on February 5, 2013
9. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
10. PDL BioPharma Announces Departure of Finance VP
11. PDL BioPharma Announces 2013 Regular Quarterly Dividends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013  AbbVie (NYSE: ABBV ... 3 clinical study called SONAR (Study Of Diabetic ... the investigational compound atrasentan - when added to standard ... patients with stage 2 to 4 chronic kidney ... a large, multinational, double-blind, placebo-controlled clinical study that ...
(Date:5/19/2013)... 20, 2013 Claret Medical, Inc. announced the publication ... Mieghem et al., Histopathology of Embolic Debris ... print in Circulation, May 7 th this research is ... Rotterdam, the Netherlands and the pathology team ... Cardiovascular Pathology Institute, Gaithersburg, Maryland.  This is ...
(Date:5/18/2013)... , May 18, 2013 Although colonoscopy exams ... considered the most sensitive method for detecting colorectal cancers ... preventing cancer cases 3 . EndoChoice ® Inc. ... system significantly improves the accuracy of this procedure and ... EndoChoice will be discussing these clinical trial results and ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3
... , July 19, 2010 Today, Novo Nordisk announced the,landmark recruitment of ... effects of modern insulins in,the management of type 2 diabetes.[1] , ... Spanning 28 countries across 4 continents and involving ... therapy. , , , ...
... Focused Ultrasound Surgery Foundation has announced that eight leading manufacturers are ... Focused Ultrasound, scheduled for October 17 through 20 near ... , , ... edge preclinical, translational and clinical research related to one of today,s ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3MR-Guided Focused Ultrasound Symposium Announces Sponsors 2MR-Guided Focused Ultrasound Symposium Announces Sponsors 3
(Date:5/20/2013)... California (PRWEB) May 20, 2013 ... done, it's not always to become a celebrity. ... May 7, 2013 ABC News report (“Chris Christie ... made it clear that the surgery was not ... candidate or gain celebrity status as a former ...
(Date:5/20/2013)... May 20, 2013 Fastcare Miami Beach ... infection (UTI) within its first symptoms, as if not treated, ... a more serious infection. Although a urinary tract infection in ... lead to serious kidney infection called pyelonephritis. Women seem to ... come up to the same percentage as women after the ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Daily Gossip, online ... provide its readers with useful tips that can help them ... , According to the website Natural Vitiligo Treatment System ... the numerous positive reviews it has received from the persons ... until now, but Daily Gossip has interviewed some of the ...
(Date:5/20/2013)... New York, NY (PRWEB) May 20, 2013 ... to protecting the rights of victims injured by defective ... South Dakota man who alleges that use of the ... The suit was filed on April 30, 2013, ... of Louisiana (Case No. 6:13-cv-0888), where it is one ...
(Date:5/20/2013)... Angeles, CA (PRWEB) May 20, 2013 According ... Wants Cancer Warnings at Indoor Tanning Salons,” tanning salons ... safety regulations. The Food and Drug Administration wants to see ... implementation of a minimum age floor of eighteen for the ... linked to concerns about melanoma, which has become increasingly common ...
Breaking Medicine News(10 mins):Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Fastcare Advises on How to Prevent a UTI 2Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2
... outstanding cancer care providers from a variety of backgrounds ... American Cancer// Society Lane Adams Quality of Life Award, ... Adams Quality of Life Award recognizes individuals who have ... in providing compassionate, skilled care, and counsel to persons ...
... child-care groups are calling on the Federal Government to fund ... bugs. ,Rotavirus puts 10,000 Australian children in hospital ... wards and at doctors' surgeries with symptoms of acute diarrhoea ... to children aged six to 32 weeks, is only available ...
... has received a US$4.1 million grant equivalent, to 49.2bn/-, ... ,According to the statement signed by AMANET Communication Officer, ... strengthening institutional capacity in health research ethics (HRE) in ... and promoting discussion, research and publications that highlight African ...
... Mozambican health units is well below the real number of ... ,Speaking in Maputo, at the opening of a national meeting ... to detect about 50 per cent of people suffering from ... TB were notified, which was an increase of five per ...
... winner of the Medgadget "Most Sci-Fi Sounding Company Name" ... their Andara OFS nerve growth stimulation system. ... a battery-powered device about the size of a cardiac ... are attached to the vertebrae at a distance of ...
... not only more inclined than younger adults to make ... to have a very high level of confidence in ... regarding the reliability of older persons’ eyewitness testimonies in ... to these results as confident but mistaken eyewitness testimony ...
Cached Medicine News:Health News:American Cancer Society Honors Exemplary Cancer Caregivers 2Health News:Call for Rotavirus Vaccine Funding 2Health News:Mozambique: Half of Tuberculosis Cases Go Undiagnosed 2Health News:Mozambique: Half of Tuberculosis Cases Go Undiagnosed 3Health News:Older Adults May Be Unreliable Eyewitness, Study Shows 2Health News:Older Adults May Be Unreliable Eyewitness, Study Shows 3
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
Conversion Kits For Modular Incubator Chamber...
... The AutoIncubator 96 can incubate and shake ... prepare 96 samples at a time. This ... and enzyme reactions, such as Proteinase K digestion. ... extraction process by preparing your samples with our ...
Inquire...
Medicine Products: